Complement Activation in the Treatment of B-Cell Malignancies

被引：5
|
作者：
Zent, Clive S. [1 ,2 ]
Pinney, Jonathan J. [3 ,4 ]
Chu, Charles C. [1 ,2 ]
Elliott, Michael R. [3 ,4 ]
机构：
[1] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14642 USA
[2] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA
[3] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA
[4] Univ Virginia, Ctr Cell Clearance, Charlottesville, VA 22908 USA
来源：
ANTIBODIES | 2020年 / 9卷 / 04期
基金：
美国国家卫生研究院;
关键词：
complement; cytotoxicity; phagocytosis; monoclonal antibody; B-cell lymphoma; chronic lymphocytic leukemia (CLL); CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTI-CD20; MONOCLONAL-ANTIBODY; PROTEIN-TYROSINE KINASE; DEPENDENT CYTOTOXICITY; CD20; ANTIBODY; IN-VITRO; MEDIATED PHAGOCYTOSIS; 1ST-LINE TREATMENT; MAC-1; CD11B/CD18; IMMUNE CLEARANCE;
D O I：
10.3390/antib9040068
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Unconjugated monoclonal antibodies (mAb) have revolutionized the treatment of B-cell malignancies. These targeted drugs can activate innate immune cytotoxicity for therapeutic benefit. mAb activation of the complement cascade results in complement-dependent cytotoxicity (CDC) and complement receptor-mediated antibody-dependent cellular phagocytosis (cADCP). Clinical and laboratory studies have showed that CDC is therapeutically important. In contrast, the biological role and clinical effects of cADCP are less well understood. This review summarizes the available data on the role of complement activation in the treatment of mature B-cell malignancies and proposes future research directions that could be useful in optimizing the efficacy of this important class of drugs.
引用
收藏
页码：1 / 14
页数：14
相关论文
共 50 条
  • [1] Lenalidomide for the treatment of B-cell malignancies
    Chanan-Khan, Asher A.
    Cheson, Bruce D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1544 - 1552
  • [2] Idelalisib for treatment of B-cell malignancies
    Do, Bryan
    Mace, Morgan
    Rexwinkle, Amber
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (08) : 547 - 555
  • [3] Idelalisib for the treatment of B-cell malignancies
    Yang, Qingshan
    Modi, Prexy
    Ramanathan, Srinivasan
    Queva, Christophe
    Gandhi, Varsha
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (01): : 109 - 123
  • [4] The use of ofatumumab in the treatment of B-cell malignancies
    Soe, Zar Ni
    Allsup, David
    FUTURE ONCOLOGY, 2017, 13 (29) : 2611 - 2628
  • [5] Proteasome inhibitors in the treatment of B-cell malignancies
    Schenkein, D
    CLINICAL LYMPHOMA, 2002, 3 (01): : 49 - 55
  • [6] DEOXYCOFORMYCIN IN THE TREATMENT OF MATURE B-CELL MALIGNANCIES
    DEARDEN, C
    CATOVSKY, D
    BRITISH JOURNAL OF CANCER, 1990, 62 (01) : 4 - 5
  • [7] Update on obinutuzumab in the treatment of B-cell malignancies
    Illidge, Tim
    Cheadle, Eleanor J.
    Donaghy, Claire
    Honeychurch, Jamie
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (10) : 1507 - 1517
  • [8] Advances and Perspectives in the Treatment of B-Cell Malignancies
    Cuenca, Marta
    Peperzak, Victor
    CANCERS, 2021, 13 (09)
  • [9] ACTIVATION OF THE COMPLEMENT CASCADE BY A PUTATIVE B-CELL SUPERANTIGEN
    KOZLOWSKI, LM
    LAMBRIS, JD
    LEVINSON, AI
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (01) : 177 - 177
  • [10] Monoclonal antibodies in the treatment of human B-cell malignancies
    Link, BK
    Weiner, GJ
    LEUKEMIA & LYMPHOMA, 1998, 31 (3-4) : 237 - 249
12345